MAximising Therapeutic Utility in Rheumatoid Arthritis
Highlights and News
- Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets - Nature
- Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets Nature
- Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis - Nature
- Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis Nature
- A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis - Nature
- A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis Nature
- Is There a Missing Link in Rheumatoid Arthritis Management? - European Medical Journal
- Is There a Missing Link in Rheumatoid Arthritis Management? European Medical Journal
- Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers
- Clinical implications of synovial tissue phenotypes in rheumatoid arthritis Frontiers
- Associations between rheumatoid arthritis clinical factors with synovial cell types and states - medRxiv
- Associations between rheumatoid arthritis clinical factors with synovial cell types and states medRxiv
- Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers
- Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy Frontiers
- Clinical Applications of Synovial Biopsy - Frontiers
- Clinical Applications of Synovial Biopsy Frontiers
- Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature
- Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial Nature
- Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes - Nature
- Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes Nature
- Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature
- Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue Nature
- Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription factor function - Nature
- Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription factor function Nature
- Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature
- Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics Nature
Related
- What is MATURA?
- EPIC-RA – Patient Survey
- Get Involved MPAG
- Highlights and News
The MATURA consortium includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis
predictive of response to biological therapy in patients with rheumatoid arthritis